Refractory chronic cough and unexplained chronic cough Refractory chronic cough and unexplained chronic cough
Conditions
Interventions
Gefapixant (45 mg, twice a day) given for 12 weeks
Chronic cough, Gefapixant, Treatment satisfaction
Sponsors
Kanemitsu Yoshihiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who visit asthma and chronic cough outpatient clinic at Nagoya City University Hospital due to refractory or unexplained chronic cough 2.patients with refractory chronic cough (RCC) and unexplained chronic cough (UCC) (8 weeks or more). RCC will be defined if cough will be refractory to intensive specific treatments for causes of chronic cough for 8 weeks or longer. 3. 18 years or older 4. Never smokers and ex-smokers with having smoking history of 20 pack-years or less. 5.Those who consented for participation in this research
Exclusion criteria
Exclusion criteria: 1. Patients with lung cancer, interstitial lung diseases, bronchiectasis, or respiratory infection such as tuberculosis and acute pneumonia. 2. Current smoker, ex-smokers with having smoking history of >20 pack-years, or those who quit smoking within six months prior to receiving gefapixant. 3. Those who are pregnant. 4. Those who were considered to be inappropriate to participate in the study by treating physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine factor related to treatment satisfaction by gefapixant in RCC and UCC patients in the multivariate regression analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate the association of changes in the core five tastes such as sweet, sour, bitter, salty, and umami by gefapixant with treatment satisfaction. 2. To evaluate what changes in the core five tastes are associated with the change in cough-specific quality of life (QoL). 3. To evaluate the association of changes in clinical indices by gefapixant with treatment satisfaction. c). To seek biomarkers that can predict the change of cough-specific quality of life by gefapixant. | — |
Contacts
Public ContactYoshihiro Kanemitsu
Nagoya City University Hospital
Outcome results
None listed